Guangzhou Kaishi Pharmaceutical Co. Ltd. has patented treprostinil derivatives acting as nitric oxide (NO) donors reported to be useful for the treatment of acute respiratory distress syndrome, pulmonary arterial hypertension and arterial occlusion.
A Chiesi Farmaceutici SpA patent details cyclohexane acid derivatives acting as lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists and thus reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Recludix Pharma Inc. has entered into a strategic collaboration with Sanofi SA to develop and commercialize first-in-class oral small-molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.
Researchers from Astrazeneca plc have presented a novel adeno-associated virus (AAV)-delivered human (h)IL-33 neutralizing scFv-based protein construct at the 2023 World Congress on Basic and Clinical Pharmacology.
Sato Pharmaceutical Co. Ltd. has divulged azaindole derivatives acting as hematopoietic prostaglandin D synthase (HPGDS) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, myocardial infarction, rheumatoid arthritis, sarcopenia and thromboangiitis obliterans (Buerger’s disease), among others.
Yingxi Intelligent Technology (Shanghai) Co. Ltd. has identified substituted monocyclic or bicyclic heterocyclic compounds acting as fibroblast growth factor receptor (FGFR) inhibitors and reported to be useful for the treatment of asthma, cancer, chronic heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammation, autoimmune and Parkinson’s disease, among others.
The FDA has awarded orphan drug designation to HL-001, a novel lysophosphatidic acid receptor-1 (LPA1) antagonist being developed for idiopathic pulmonary fibrosis (IPF) by Ube Corp. and Hilung Inc.
ΔF508 is the most prevalent mutation detected in patients with cystic fibrosis (CF), and it causes a loss of F508 within CFTR’s first nucleotide binding domain (NBD1). Researchers from Sionna Therapeutics Inc. recently reported the discovery and preclinical evaluation of novel small-molecule CFTR NBD1 stabilizers and CFTR assembly correctors as potential new agents for the treatment of CF.
Anoat Therapeutics has raised €2 million (US$2.17 million) in seed funding to develop novel therapies for cystic fibrosis. The financing comes from a seed funding partnership between Adbio Partners SAS and Inserm Transfert SA.
RSS
